查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2102744

蛋白酪氨酸激酶抑制劑市場：全球市場預測，2026-2032年

Tyrosine Kinase Inhibitors Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，蛋白酪氨酸激酶抑制劑市場規模將達到 1,117.5 億美元，複合年成長率為 7.30%。

主要市場統計數據
基準年 2025 682.1億美元
預計年份：2026年 733.6億美元
預測年份 2032 1117.5億美元
複合年成長率 (%) 7.30%

蛋白酪氨酸激酶抑制劑（TKIs）已成為標靶治療的核心組成部分，尤其是在腫瘤學以及某些免疫介導和發炎性疾病領域，這些疾病中激酶訊號傳導異常會加速疾病進展。透過抑制與細胞增殖、血管生成、免疫活化和腫瘤存活相關的通路中異常的蛋白酪氨酸激酶活性，這些療法重新定義了慢性骨髓性白血病、非小細胞胃腸道基質腫瘤、乳癌亞型以及多種骨髓惡性腫瘤的標準治療方案。精準醫療、基於生物標記的處方、伴隨診斷、抗藥性管理以及旨在提高選擇性、耐受性和對抗抗藥性突變活性的新一代抑制劑日益成長的臨床意義，正推動著該領域的商業環境發展。監管機構持續支持癌症治療領域的加速創新，前提是必須有強力的臨床證據證明其具有顯著的治療效果；而醫療體系則強調真實世界數據、藥物安全監測以及基於價值的醫療服務獲取。隨著蛋白酪氨酸激酶抑制劑領域的發展，相關人員需要將科學創新與診斷基礎設施、公平取得、生命週期管理以及在不同患者群體中產生證據相結合。

蛋白酪氨酸激酶抑制劑領域的變革性變化

隨著治療策略從廣泛的疾病分類轉向基於分子特徵的患者群體，蛋白酪氨酸激酶抑制劑領域正經歷著變革性的轉變。基因組檢測、液態生物檢體、次世代定序和腫瘤譜分析技術的進步，大大拓展了識別潛在治療標靶突變和融合的能力，這些突變和融合涉及EGFR、ALK、ROS1、BCR-ABL、HER2、FLT3、RET、MET、NTRK、JAK、BTK和VEGFR等訊號通路。這增加了對具有更高激酶選擇性、更強中樞神經系統穿透性、更佳安全性管理以及對抗獲得性抗藥性機制的療法的需求。臨床研發擴大採用適應性試驗設計、籃式試驗、傘式試驗和生物標記篩選隊列，這些方法能夠加速罕見基因組突變證據的生成。同時，治療模式正轉向聯合治療策略，將酪胺酸激酶抑制劑（TKI）與免疫療法、化療、內分泌療法、抗血管新生藥物、抗體療法和其他標靶治療結合，需要仔細評估毒性、給藥順序和患者選擇。雖然專利到期和學名藥的出現正在影響某些市場的支付方政策和成本效益，但新藥仍然憑藉其安全性、抗藥性覆蓋範圍、給藥便利性、療效持續時間和生活品質（QOL）結果而脫穎而出。這些變化使得診斷系統的發展、納入臨床指引以及上市後證據對於建立競爭優勢至關重要。

人工智慧對蛋白酪氨酸激酶抑制劑的累積影響

人工智慧 (AI) 透過提高研發、診斷和患者管理的速度、準確性和效率，對整個蛋白酪氨酸激酶抑制劑生態系統產生了累積影響。在藥物發現階段，AI 驅動的建模有助於標靶識別、激酶選擇性預測、分子對接、毒性篩檢以及最佳化具有更優藥物動力學特性的化合物。在臨床開發階段，機器學習能夠實現更精細的患者分層、基於生物標記的亞組識別、最佳化臨床試驗中心選擇以及對複雜的多組體學、病理學、影像學和縱向結局資料集的分析。 AI 驅動的病理學和影像診斷工具與檢驗的臨床實驗工作流程相結合，可增強對治療反應和疾病監測的評估。在臨床實務中，先進的分析技術有助於深入了解治療順序、檢測不利事件、監測用藥依從性，並評估臨床試驗中常被低估的患者群體（例如老年患者和合併症患者）的治療結果。然而，其應用必須基於符合監管標準的證據、透明的模型檢驗、資料隱私保護、減少偏差以及與電子健康記錄（EHR）和實驗室資訊系統（LIS）的互通性。對於產業領導者而言，最合理的AI策略並非取代醫師的判斷，而是加速生物標記的發現、改善臨床試驗的實施、加強藥物安全監測並產生臨床適用的證據。

蛋白酪氨酸激酶抑制劑的關鍵區域性見解

由於癌症診斷數量的增加、基因組檢測能力的提升以及標靶癌症療法在多個癌症患者大國的廣泛應用，亞太地區對蛋白酪氨酸激酶抑制劑（TKI）的重要性日益凸顯。儘管中國、日本、韓國、印度和澳洲透過參與臨床研究、監管現代化、建立分子腫瘤學委員會以及投資次世代定序和伴隨診斷等舉措，正在推進精準癌症治療，但都市區三級醫療機構與農村醫療系統之間在醫療服務獲取方面仍然存在差距。北美地區在TKI應用方面仍然高度成熟，這得益於其強大的腫瘤學基礎設施、臨床指南的持續實施、許多醫療機構中生物標記檢測的完善醫保報銷機制以及較高的腫瘤臨床試驗參與率。美國在標靶治療研究創新和真實世界數據（REW）生成方面發揮核心作用，而加拿大則專注於衛生技術評估（HTA）以及各省醫療系統間醫療服務的公平獲取。在歐洲，實證TKI療法正透過集中監管評估、國家醫保報銷流程、藥物安全監測以及完善的癌症網路而日益普及。德國、法國、義大利、西班牙和英國尤其在規範臨床實踐和建立分子腫瘤學委員會方面發揮了主導作用。在拉丁美洲，巴西和墨西哥正在穩步推進腫瘤服務和診斷能力的提升，但醫保報銷限制、保險覆蓋範圍分散以及專科醫療資源分配不均等問題仍然影響著患者的就醫。在中東，透過對公共衛生、專科癌症中心和分子診斷的廣泛投資，腫瘤基礎設施正在加強。這一趨勢在海灣高所得國家尤為顯著，精準醫療的進展日益明顯。非洲仍然是腫瘤標靶治療的普及受到許多因素的阻礙，例如診斷延遲、分子檢測能力不足、經濟障礙、複雜的供應鏈以及腫瘤專科醫生分佈不均等。因此，在診斷、培訓和基本癌症護理夥伴關係對於確保未來獲得 TKI 至關重要。

蛋白酪氨酸激酶抑制劑的關鍵組別分析

在東南亞國協，隨著癌症中心分子檢測和專科治療能力的提升，蛋白酪氨酸激酶抑制劑（TKI）正日益被納入腫瘤治療方案；然而，由於醫保覆蓋範圍、病理基礎設施、基因組檢測的普及程度以及訓練有素的腫瘤專科醫生數量等因素，各成員國之間的TKI可及性存在顯著差異。在海灣合作理事會（GCC）國家，隨著對精準醫療和癌症篩檢的日益重視，透過對先進癌症中心的投資、國家癌症戰略、政府資助的醫療保健計劃以及跨境專科診療，TKI的應用正在得到加強。歐盟為TKI的評估和應用提供了最為完善的環境之一，它將集中化的藥物核准體系與國家衛生技術評估、藥物安全監測系統、基於指南的癌症治療以及支持基因組醫學的各項舉措相結合。然而，各成員國的健保覆蓋範圍和病患可近性可能存在差異。金磚國家（BRICS）構成了一個多元化但對蛋白酪氨酸激酶抑制劑（TKI）具有重要戰略意義的群體。這是因為，儘管這些國家擁有龐大的患者群體、不斷擴展的臨床研究能力、日益成長的國內醫療保健投資以及分子診斷的廣泛應用，但它們仍然面臨著經濟負擔、檢測可及性以及區域間可及性差異等挑戰。在七國集團（G7）國家，酪胺酸激酶抑制劑（TKI）通常已高度整合到標準腫瘤治療路徑中，並得到先進診斷技術、臨床試驗體系、成熟的監管體系、健全的藥物安全監測系統以及基於真實世界數據的證據框架的支持。然而，成本控制和價值主張仍然是持續的政策重點。北約成員國與北美和歐洲的先進醫療保健體系高度重合，在這些地區，TKI的供應通常得到強力的法律規範和腫瘤基礎設施的支持；然而，TKI的可及性仍然取決於國家醫保報銷政策、區域臨床能力、處方藥清單的控制以及生物標記檢測的範圍。

主要國家蛋白酪氨酸激酶抑制劑的發展趨勢

由於精準腫瘤學的廣泛應用、大規模生物標記檢測、積極的臨床試驗以及標靶治療快速整合到專科醫療路徑中，美國在蛋白酪氨酸激酶抑製劑（TKI）領域持續主導。在加拿大，實證TKI的使用十分普遍，其可近性受到省級醫保報銷決策、衛生技術評估以及持續推進基因組檢測公平性等因素的影響。在墨西哥，標靶癌症治療在主要大都會地區正在取得進展，但分散的保險體系、經濟負擔以及分子診斷的可近性差異可能會影響患者的用藥。在巴西，癌症醫療基礎設施正在發展，TKI在公立和私立醫療系統中的使用均有所增加，但診斷的可近性和報銷時間仍然是重要的差異因素。在英國，國家治療指南、基因組醫學舉措、臨床和經濟證據的統一評估以及針對特定抗癌藥物的系統性獲取途徑為TKI的使用提供了支持。德國受益於成熟的癌症診療體系、強大的診斷能力以及專家們的快速採納；法國則強調系統化的保險報銷、協調的癌症網路和藥物安全監測。在俄羅斯，對標靶癌症療法的需求仍然存在，但能否獲得治療取決於公共採購、國家政策重點和區域醫療能力。在義大利和西班牙，酪胺酸激酶抑制劑（TKI）的使用是基於已建立的癌症診療網路和指南，但治療的可近性可能受到區域報銷機制和醫院藥物採納流程的影響。在中國，大規模的癌症患者群體和不斷成長的國內創新能力為TKI的研究、法規核准和分子檢測能力提供了支持，使其迅速發展。在印度，隨著診斷技術和癌症診療服務的擴展，蛋白酪氨酸激酶抑制劑的使用也在增加，但經濟負擔、自付費用和區域差異仍然是主要考慮因素。日本在標靶治療的引入方面擁有長期累積的經驗、健全的管理體制以及先進診斷技術的整合，尤其是在肺癌和骨髓惡性腫瘤。澳洲擁有高品質的癌症治療、保險報銷評估、國家級精準醫療舉措和專業的癌症治療服務，而韓國憑藉其先進的醫院系統、基因組檢測能力、數位健康基礎設施以及積極參與癌症研究，在TKI的臨床應用方面取得了顯著進展。

為行業領導者提供的實用建議

產業領導者應優先考慮以生物標記為導向的研發策略，將TKI創新與檢驗的診斷路徑、真實世界數據和明確的臨床差異化相結合。投資下一代激酶選擇性、抗藥性突變覆蓋率、最佳化耐受性、中樞神經系統效應以及聯合治療證據，對於跟上不斷發展的治療標準至關重要。各機構應制定區域准入計劃，其中應考慮報銷要求、醫療技術評估預期、診斷可用性、經濟限制和當地治療指南。擴大與認證實驗室、癌症中心、學術研究人員、患者團體和數位健康平台的夥伴關係，有助於改善患者識別、臨床試驗招募和長期療效追蹤。領導者也應加強藥物安全性監測，以監測多種TKI類別通用的臨床相關不利事件，例如心臟毒性、肝毒性、皮膚反應、間質性肺病、高血壓、骨髓抑制、出血風險和藥物交互作用。為提升公平性，相關人員應支持臨床醫生教育、分子檢測的普及、病人支持體系的建設、分散式證據的建構以及針對被忽視人群的研究。人工智慧的應用應僅限於檢驗的用例，例如生物標記發現、臨床試驗最佳化、安全性監測、影像分析和真實世界資料分析，並且必須建立管治結構，以確保透明度、隱私保護、互通性、減少偏差並符合監管要求。

蛋白酪氨酸激酶抑制劑分析的調查方法

評估蛋白酪氨酸激酶抑制劑的調查方法應整合檢驗的二級研究、基於專家意見的一級研究結果、監管審查、臨床指南評估以及真實世界證據分析。可靠的資訊來源包括同儕審查的醫學文獻、臨床試驗註冊庫、法規核准文件、處方資訊、藥物安全監測資料庫、腫瘤治療指南、衛生技術評估報告、醫院規程參考資料以及來自權威衛生機構的公開流行病學資源。一級研究應包括對腫瘤科醫生、血液科醫生、病理學家、分子診斷專家、藥劑師、保險公司、臨床研究人員和醫療保健管理人員進行結構化訪談，以檢驗治療採納模式、生物標記檢測實踐、獲取障礙、安全性考慮因素以及未滿足的需求。分析中的三角驗證應比較臨床證據、監管環境、診斷準備、報銷條件和當地醫療保健基礎設施，而不應依賴未經證實的假設。市場細分應考慮標靶激酶路徑、治療適應症、抑制劑類型、治療線數、給藥途徑、患者生物標記狀態、抗藥性突變譜以及醫療服務環境。品管應包括檢驗資料資訊來源、確認資料時效性、核對監管和臨床聲明，並剔除推測性預測。本調查方法能夠提供平衡、基於證據且以商業為導向的TKI整體情況觀點，同時避免對市場規模、市場佔有率和預測做出任何斷言。

結論

蛋白酪氨酸激酶抑制劑 (TKI) 透過將分子層面的疾病生物學轉化為腫瘤及某些非腫瘤適應症的標靶治療策略，不斷重新定義精準醫療的概念。該領域的未來發展方向取決於生物標記檢測的擴展、下一代抑制劑的設計、抗藥性管理、聯合治療、真實世界數據以及人工智慧驅動的研究能力。成熟的醫療體繫著重於價值、安全性、治療順序以及與診斷的整合，而新興地區則致力於解決分子檢測、經濟負擔和專科醫生診療方面的差異。持續成功的關鍵在於將科學進步與臨床效用結合，確保證據符合監管標準，負責任地使用數據，並保障患者公平地獲得醫療服務。對於決策者而言，最關鍵的優先事項顯而易見：加強診斷生態系統，產生差異化的臨床證據，解決抗藥性和耐受性問題，支持區域性進入策略，並利用人工智慧改善可衡量的治療效果。在不斷變化的環境中，蛋白酪氨酸激酶抑制劑仍然是標靶治療創新的核心，並將繼續透過精準醫療、個人化醫療和實證護理影響現代治療途徑。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：蛋白酪氨酸激酶抑制劑市場：以標靶分類

  • ALK
  • BCR-ABL
  • EGFR
  • VEGFR

第8章：蛋白酪氨酸激酶抑制劑市場：依藥物世代分類

  • 第一代TKI
  • 第二代酪胺酸激酶抑制劑
  • 第三代酪胺酸激酶抑制劑

第9章：蛋白酪氨酸激酶抑制劑市場：依適應症分類

  • 乳癌
  • 慢性骨髓性白血病
  • 非小細胞肺癌
  • 腎臟細胞癌

第10章：蛋白酪氨酸激酶抑制劑市場：依給藥途徑分類

  • 靜脈
  • 口服

第11章：蛋白酪氨酸激酶抑制劑市場：依通路分類

  • 醫院藥房
  • 零售藥房

第12章：蛋白酪氨酸激酶抑制劑市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：蛋白酪氨酸激酶抑制劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：蛋白酪氨酸激酶抑制劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • BeiGene Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Chugai Pharmaceutical Co., Ltd.
  • Daiichi Sankyo Company, Limited
  • Deciphera Pharmaceuticals, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • GSK plc
  • Incyte Corporation
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Rigel Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Zai Lab Limited
Product Code: MRR-B168537796FC

The Tyrosine Kinase Inhibitors Market is projected to grow by USD 111.75 billion at a CAGR of 7.30% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 68.21 billion
Estimated Year [2026] USD 73.36 billion
Forecast Year [2032] USD 111.75 billion
CAGR (%) 7.30%

Tyrosine kinase inhibitors (TKIs) have become a core pillar of targeted therapy, especially across oncology and select immune-mediated and inflammatory conditions where dysregulated kinase signaling drives disease progression. By blocking abnormal tyrosine kinase activity in pathways linked to cell growth, angiogenesis, immune activation, and tumor survival, these therapies have reshaped treatment standards for chronic myeloid leukemia, non-small cell lung cancer, renal cell carcinoma, gastrointestinal stromal tumors, breast cancer subtypes, and multiple hematologic malignancies. The executive landscape is increasingly defined by precision medicine, biomarker-driven prescribing, companion diagnostics, resistance management, and the growing clinical relevance of next-generation inhibitors designed to improve selectivity, tolerability, and activity against resistant mutations. Regulatory agencies continue to support accelerated oncology innovation where robust clinical evidence demonstrates meaningful outcomes, while healthcare systems emphasize real-world evidence, pharmacovigilance, and value-based access. As the tyrosine kinase inhibitors landscape evolves, stakeholders must align scientific innovation with diagnostic infrastructure, equitable access, lifecycle management, and evidence generation across diverse patient populations.

Transformative Shifts in the Tyrosine Kinase Inhibitors Landscape

The tyrosine kinase inhibitors landscape is undergoing transformative shifts as treatment strategies move from broad disease categories toward molecularly defined patient segments. Advances in genomic testing, liquid biopsy, next-generation sequencing, and tumor profiling have expanded the ability to identify actionable mutations and fusions involving pathways such as EGFR, ALK, ROS1, BCR-ABL, HER2, FLT3, RET, MET, NTRK, JAK, BTK, and VEGFR. This has intensified demand for therapies with higher kinase selectivity, improved central nervous system penetration, better safety management, and activity against acquired resistance mechanisms. Clinical development is increasingly shaped by adaptive trial designs, basket trials, umbrella trials, and biomarker-enriched cohorts that can accelerate evidence generation for rare genomic alterations. At the same time, the therapeutic paradigm is shifting toward combination strategies involving TKIs with immunotherapies, chemotherapy, endocrine therapy, anti-angiogenic agents, antibody-based therapies, and other targeted treatments, requiring careful evaluation of toxicity, sequencing, and patient selection. Patent expiries and generic availability are influencing payer policies and treatment affordability in several markets, while novel agents continue to differentiate through safety profiles, resistance coverage, dosing convenience, durability of response, and quality-of-life outcomes. These shifts are making diagnostic readiness, clinical guideline integration, and post-approval evidence central to competitive positioning.

Cumulative Impact of Artificial Intelligence on Tyrosine Kinase Inhibitors

Artificial intelligence is creating cumulative impact across the tyrosine kinase inhibitors ecosystem by improving the speed, precision, and efficiency of research, clinical development, diagnostics, and patient management. In discovery, AI-enabled modeling supports target identification, kinase selectivity prediction, molecular docking, toxicity screening, and optimization of compounds with improved pharmacokinetic properties. In clinical development, machine learning can help refine patient stratification, identify biomarker-defined subgroups, optimize trial site selection, and analyze complex multi-omics, pathology, radiology, and longitudinal outcomes datasets. AI-assisted pathology and radiology tools are also strengthening response assessment and disease monitoring when integrated with validated clinical workflows. In real-world settings, advanced analytics can support treatment sequencing insights, adverse event detection, adherence monitoring, and evaluation of outcomes among patients often underrepresented in trials, including older adults and individuals with comorbidities. However, adoption must remain grounded in regulatory-grade evidence, transparent model validation, data privacy safeguards, bias mitigation, and interoperability with electronic health records and laboratory information systems. For industry leaders, the most defensible AI strategies are those that enhance biomarker discovery, improve trial execution, strengthen pharmacovigilance, and generate clinically actionable evidence without replacing physician judgment.

Key Regional Insights for Tyrosine Kinase Inhibitors

Asia-Pacific is becoming increasingly important for tyrosine kinase inhibitors due to rising cancer diagnosis volumes, expanding genomic testing capacity, and broader adoption of targeted oncology care in countries with large patient populations. China, Japan, South Korea, India, and Australia are advancing precision oncology through clinical research participation, regulatory modernization, molecular tumor boards, and investments in next-generation sequencing and companion diagnostics, although access remains uneven between urban tertiary centers and rural healthcare systems. North America remains a highly mature region for TKI adoption, supported by extensive oncology infrastructure, strong clinical guideline implementation, established reimbursement pathways for biomarker testing in many settings, and high participation in oncology trials. The United States anchors innovation in targeted therapy research and real-world evidence generation, while Canada emphasizes health technology assessment and equitable access across provincial systems. Europe demonstrates strong uptake of evidence-based TKI therapy through centralized regulatory evaluation, national reimbursement processes, pharmacovigilance, and well-developed cancer networks, with Germany, France, Italy, Spain, and the United Kingdom playing major roles in clinical practice standardization and molecular tumor board adoption. Latin America is progressing steadily as Brazil and Mexico expand oncology services and diagnostic capabilities, though reimbursement limitations, fragmented insurance coverage, and disparities in specialty care continue to influence access. The Middle East is strengthening oncology infrastructure through public health investment, specialist cancer centers, and growing adoption of molecular diagnostics, particularly in high-income Gulf countries where precision medicine initiatives are increasingly visible. Africa remains the most access-constrained region, with targeted therapy uptake affected by late diagnosis, limited molecular testing capacity, affordability barriers, supply-chain complexity, and uneven oncology workforce distribution, making partnerships in diagnostics, training, and essential cancer care critical to future TKI access.

Key Group Insights for Tyrosine Kinase Inhibitors

ASEAN countries are increasingly incorporating tyrosine kinase inhibitors into oncology protocols as cancer centers expand molecular testing and specialist treatment capacity, but access varies widely across member states based on reimbursement depth, pathology infrastructure, genomic testing coverage, and availability of trained oncology professionals. The GCC is strengthening adoption through investment in advanced cancer centers, national oncology strategies, government-funded healthcare systems, and cross-border specialist care, with demand shaped by growing emphasis on precision medicine and cancer screening. The European Union provides one of the most structured environments for TKI assessment and use, combining centralized medicine authorization with national health technology assessment, pharmacovigilance systems, guideline-driven oncology care, and initiatives supporting genomic medicine; however, timing of reimbursement and patient access can differ across member countries. BRICS countries represent a diverse but strategically important group for tyrosine kinase inhibitors because they include large patient populations, growing clinical research capability, expanding domestic healthcare investment, and increasing use of molecular diagnostics, while still facing disparities in affordability, testing availability, and regional access. G7 countries generally show high integration of TKIs into standard oncology pathways, supported by advanced diagnostics, clinical trial ecosystems, regulatory maturity, robust pharmacovigilance, and real-world evidence frameworks, though cost containment and value demonstration remain persistent policy priorities. NATO member countries overlap significantly with advanced North American and European healthcare systems, where TKI availability is often supported by strong regulatory oversight and oncology infrastructure, but access patterns still depend on national reimbursement decisions, local clinical capacity, formulary management, and biomarker testing coverage.

Key Country Insights for Tyrosine Kinase Inhibitors

The United States remains a leading country for tyrosine kinase inhibitors due to broad precision oncology adoption, extensive biomarker testing, robust clinical trial activity, and rapid integration of targeted therapies into specialist care pathways. Canada demonstrates strong evidence-based use of TKIs, with access influenced by provincial reimbursement decisions, health technology assessments, and ongoing efforts to expand genomic testing equity. Mexico is advancing targeted oncology care in major urban centers, though patient access can be affected by insurance fragmentation, affordability, and uneven molecular diagnostic availability. Brazil has a growing oncology infrastructure and increasing use of TKIs in both public and private systems, but diagnostic access and reimbursement timing remain key differentiators. The United Kingdom supports TKI use through national treatment guidelines, genomic medicine initiatives, centralized evaluation of clinical and economic evidence, and structured access routes for selected oncology medicines. Germany benefits from a mature oncology care ecosystem, strong diagnostic capabilities, and rapid specialist adoption, while France emphasizes structured reimbursement, cancer network coordination, and pharmacovigilance. Russia maintains demand for targeted oncology treatments, with access shaped by public procurement, domestic policy priorities, and regional healthcare capacity. Italy and Spain have well-established oncology networks and guideline-based TKI use, although regional reimbursement and hospital formulary processes can influence treatment availability. China is rapidly expanding TKI research, regulatory approvals, and molecular testing capacity, supported by a large oncology patient base and growing domestic innovation. India shows rising use of tyrosine kinase inhibitors as diagnostics and oncology services expand, but affordability, out-of-pocket spending, and geographic disparities remain major considerations. Japan has long-standing expertise in targeted therapy adoption, strong regulatory systems, and advanced diagnostic integration, particularly in lung cancer and hematologic malignancies. Australia combines high-quality oncology care, reimbursement evaluation, national precision medicine initiatives, and specialist cancer services, while South Korea demonstrates strong clinical adoption of TKIs through advanced hospital systems, genomic testing capabilities, digital health infrastructure, and active participation in oncology research.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-aligned development strategies that connect TKI innovation with validated diagnostic pathways, real-world evidence, and clear clinical differentiation. Investment in next-generation kinase selectivity, resistance mutation coverage, tolerability optimization, central nervous system activity, and combination therapy evidence will be essential to address evolving standards of care. Organizations should build region-specific access plans that account for reimbursement requirements, health technology assessment expectations, diagnostic availability, affordability constraints, and local treatment guidelines. Expanding partnerships with accredited laboratories, cancer centers, academic investigators, patient organizations, and digital health platforms can improve patient identification, trial recruitment, and longitudinal outcome tracking. Leaders should also strengthen pharmacovigilance systems to monitor adverse events such as cardiotoxicity, hepatotoxicity, dermatologic reactions, interstitial lung disease, hypertension, myelosuppression, bleeding risk, and drug-drug interactions, which are clinically relevant across multiple TKI classes. To improve equity, stakeholders should support clinician education, molecular testing access, patient assistance frameworks, decentralized evidence generation, and studies in underrepresented populations. AI adoption should be targeted toward validated use cases, including biomarker discovery, trial optimization, safety monitoring, imaging analytics, and real-world data analytics, with governance frameworks that ensure transparency, privacy, interoperability, bias mitigation, and regulatory compliance.

Research Methodology for Tyrosine Kinase Inhibitors Analysis

The research methodology for evaluating tyrosine kinase inhibitors should integrate validated secondary research, expert-informed primary insights, regulatory review, clinical guideline assessment, and real-world evidence analysis. Reliable sources include peer-reviewed medical literature, clinical trial registries, regulatory approval documents, prescribing information, pharmacovigilance databases, oncology treatment guidelines, health technology assessment reports, hospital protocol references, and publicly available epidemiological resources from recognized health authorities. Primary research should involve structured interviews with oncologists, hematologists, pathologists, molecular diagnostic specialists, pharmacists, payers, clinical researchers, and healthcare administrators to validate treatment adoption patterns, biomarker testing practices, access barriers, safety considerations, and unmet clinical needs. Analytical triangulation should compare clinical evidence, regulatory status, diagnostic readiness, reimbursement conditions, and regional healthcare infrastructure without relying on unsupported assumptions. Segmentation should consider target kinase pathway, therapeutic indication, generation of inhibitor, line of therapy, route of administration, patient biomarker status, resistance mutation profile, and care setting. Quality controls should include source verification, date relevance, cross-checking of regulatory and clinical claims, and exclusion of speculative projections. This methodology supports a balanced, evidence-based executive view of the TKI landscape while avoiding market sizing, market share, and forecasting claims.

Conclusion

Tyrosine kinase inhibitors continue to redefine precision medicine by translating molecular disease biology into targeted therapeutic strategies across oncology and selected non-oncology indications. The sector's future direction is being shaped by biomarker testing expansion, next-generation inhibitor design, resistance management, combination regimens, real-world evidence, and AI-enabled research capabilities. Mature healthcare systems are focusing on value, safety, sequencing, and diagnostic integration, while emerging regions are working to close gaps in molecular testing, affordability, and specialist access. Sustainable success will depend on aligning scientific advancement with clinical utility, regulatory-grade evidence, responsible data use, and equitable patient access. For decision-makers, the most important priorities are clear: strengthen diagnostic ecosystems, generate differentiated clinical evidence, address resistance and tolerability, support regional access strategies, and use artificial intelligence where it improves measurable outcomes. In this evolving landscape, tyrosine kinase inhibitors remain central to targeted therapy innovation and will continue to influence modern treatment pathways through precision, personalization, and evidence-based care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Tyrosine Kinase Inhibitors Market, by Target

  • 7.1. Introduction
  • 7.2. ALK
  • 7.3. BCR-ABL
  • 7.4. EGFR
  • 7.5. VEGFR

8. Tyrosine Kinase Inhibitors Market, by Drug Generation

  • 8.1. Introduction
  • 8.2. First-Generation TKIs
  • 8.3. Second-Generation TKIs
  • 8.4. Third-Generation TKIs

9. Tyrosine Kinase Inhibitors Market, by Indication

  • 9.1. Introduction
  • 9.2. Breast Cancer
  • 9.3. Chronic Myeloid Leukemia
  • 9.4. Non Small Cell Lung Cancer
  • 9.5. Renal Cell Carcinoma

10. Tyrosine Kinase Inhibitors Market, by Route Of Administration

  • 10.1. Introduction
  • 10.2. Intravenous
  • 10.3. Oral

11. Tyrosine Kinase Inhibitors Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacies
  • 11.3. Retail Pharmacies

12. Tyrosine Kinase Inhibitors Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Tyrosine Kinase Inhibitors Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Tyrosine Kinase Inhibitors Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc.
  • 16.2. Amgen Inc.
  • 16.3. Astellas Pharma Inc.
  • 16.4. AstraZeneca plc
  • 16.5. Bayer AG
  • 16.6. BeiGene Ltd.
  • 16.7. Boehringer Ingelheim International GmbH
  • 16.8. Bristol-Myers Squibb Company
  • 16.9. Chugai Pharmaceutical Co., Ltd.
  • 16.10. Daiichi Sankyo Company, Limited
  • 16.11. Deciphera Pharmaceuticals, Inc.
  • 16.12. Eisai Co., Ltd.
  • 16.13. Eli Lilly and Company
  • 16.14. Exelixis, Inc.
  • 16.15. GSK plc
  • 16.16. Incyte Corporation
  • 16.17. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • 16.18. Johnson & Johnson
  • 16.19. Merck & Co., Inc.
  • 16.20. Novartis AG
  • 16.21. Ono Pharmaceutical Co., Ltd.
  • 16.22. Pfizer Inc.
  • 16.23. Rigel Pharmaceuticals, Inc.
  • 16.24. Roche Holding AG
  • 16.25. Sanofi S.A.
  • 16.26. Takeda Pharmaceutical Company Limited
  • 16.27. Zai Lab Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL TYROSINE KINASE INHIBITORS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL TYROSINE KINASE INHIBITORS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL TYROSINE KINASE INHIBITORS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL TYROSINE KINASE INHIBITORS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL TYROSINE KINASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL TYROSINE KINASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL TYROSINE KINASE INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ALK MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALK MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ALK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BCR-ABL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BCR-ABL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BCR-ABL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EGFR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EGFR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EGFR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VEGFR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VEGFR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VEGFR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FIRST-GENERATION TKIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FIRST-GENERATION TKIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FIRST-GENERATION TKIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SECOND-GENERATION TKIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SECOND-GENERATION TKIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SECOND-GENERATION TKIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL THIRD-GENERATION TKIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL THIRD-GENERATION TKIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL THIRD-GENERATION TKIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NON SMALL CELL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RENAL CELL CARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RENAL CELL CARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RENAL CELL CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 99. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 100. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 117. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 118. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 119. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 123. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 124. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 129. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 136. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 137. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 138. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 142. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 143. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 147. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 148. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 149. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 160. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 161. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 166. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 167. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 172. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 173. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 178. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 179. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 184. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 185. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 196. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 197. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 198. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 202. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 203. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 208. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 209. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 210. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 214. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG GENERATION, 2018-2032 (USD MILLION)
  • TABLE 215. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL TYROSINE KINASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 219. GLOBAL TYROSINE KINASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025